Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
Silje Agnethe Stokke KvistadJoachim BurmanAnne Kristine LehmannAndreas TolfChristina ZjukovskajaGuro Kristin MelveLars BøØivind TorkildsenPublished in: Journal of neurology, neurosurgery, and psychiatry (2022)
This study provides level 4 evidence that AHSCT in patients previously treated with alemtuzumab, cladribine or rituximab is safe and efficacious.